Key clinical point: Andexanet alfa significantly reduces anti–factor Xa activity.
Major finding: Approximately 82% of treated patients achieved good or excellent hemostasis.
Study details: A single-cohort study of 352 patients with acute major bleeding associated with factor Xa inhibition.
Disclosures: Portola Pharmaceuticals, the maker of andexanet alfa, funded the study.
Milling TJ et al. ISC 2019, Abstract LB7.